{
  "id": "adv_mhgap#referral_da3a3455",
  "content": "6 months on medication is needed to determine full\neffectiveness of maintenance treatment.\nSODIUM VALPROATE Start 500 mg daily. Common: sedation, headache, tremor, ataxia, nausea, Caution in patients with: underlying or suspected hepatic disease.\nIncrease slowly to 1000-2000 mg daily vomiting, diarrhea, weight gain, transient hair loss. Monitor liver function tests and platelets if possible.\n(maximum 60 mg/kg/day).\nSerious: impaired hepatic function, Drug-drug interactions:\nRoute: p.o\nthrombocytopenia, leucopenia, drowsiness/ Valproate levels decreased by carbamazepine, increased by aspirin.\nPreferred choice in persons living with confusion, liver failure, hemorrhagic pancreatitis.\nHIV\nHIV/AIDS due to drug-drug interactions.\nCARBAMAZEPINE Start 200 mg daily. Common: sedation, confusion, dizziness, ataxia, Contraindicated in patients with: history of blood disorders,\nIncrease by 200 mg weekly to 400-600 mg daily in double vision, nausea, diarrhea, benign leucopenia. kidney, liver, or cardiac disease.\ntwo divided doses (maximum 1200 mg daily).\nSerious: hepatotoxicity, cardiac conduction delay, Drug-drug interactions.\nRoute: p.o\nlow sodium levels, severe rash. – May reduce the effects of hormonal birth control, immunosuppressants,\nNote: Dose may need to be adjusted after antiepileptics, antipsychotics, methadone and some antiretrovirals.\n2 weeks due to induction of its own metabolism. – Levels can be increased by certain antifungals and antibiotics.\nPSYCHOSES 43\n44",
  "metadata": {
    "source": "WHO mhGAP-IG 2023",
    "url": "https://www.who.int/",
    "condition": "General",
    "risk_band": "low",
    "topics": [
      "emotions",
      "referral",
      "management"
    ],
    "is_clinical": true,
    "is_advice": true
  },
  "index_text": "General — Referral 6 months on medication is needed to determine full\neffectiveness of maintenance treatment.\nSODIUM VALPROATE Start 500 mg daily. Common: sedation, headache, tremor, ataxia, nausea, Caution in patients with: underlying or suspected hepatic disease.\nIncrease slowly to 1000-2000 mg daily vomiting, diarrhea, weight gain, transient hair loss. Monitor liver function tests and platelets if possible.\n(maximum 60 mg/kg/day).\nSerious: impaired hepatic function, Drug-drug interactions:\nRoute: p.o\nthrombocytopenia, leucopenia, drowsiness/ Valproate levels decreased by carbamazepine, increased by aspirin.\nPreferred choice in persons living with confusion, liver failure, hemorrhagic pancreatitis.\nHIV\nHIV/AIDS due to drug-drug interactions.\nCARBAMAZEPINE Start 200 mg daily. Common: sedation, confusion, dizziness, ataxia, Contraindicated in patients with: history of blood disorders,\nIncrease by 200 mg weekly to 400-600 mg daily in double vision, nausea, diarrhea, benign leucopenia. kidney, liver, or cardiac disease.\ntwo divided doses (maximum 1200 mg daily).\nSerious: hepatotoxicity, cardiac conduction delay, Drug-drug interactions.\nRoute: p.o\nlow sodium levels, severe rash. – May reduce the effects of hormonal birth control, immunosuppressants,\nNote: Dose may need to be adjusted after antiepileptics, antipsychotics, methadone and some antiretrovirals.\n2 weeks due to induction of its own metabolism. – Levels can be increased by certain antifungals and antibiotics.\nPSYCHOSES 43\n44 6 months on medication is needed to determine full\neffectiveness of maintenance treatment. sodium valproate start 500 mg daily."
}